Navigation Links
Roche launches DISCOVERY 5-Plex procedure for cancer research applications

TUCSON, Ariz., Nov. 21, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the launch of its DISCOVERY 5-Plex procedure and reagents1 for immunohistochemistry (IHC) research applications. This is the first pre-optimized, fully automated multiplex procedure available on the VENTANA DISCOVERY ULTRA2 instrument.

Scientists globally are faced with the growing need to extract more information from limited tissue samples. DISCOVERY 5-Plex procedure allows researchers to investigate up to five biomarkers on a single slide, preserving tissue and maximizing data. The procedure provides researchers with a pre-optimized workflow that simplifies the staining process. The ready-to-use detection reagents provide crisp, specific signals and distinct information about protein co-expression patterns.

Continue Reading
Lung tissue at 40x magnification using the DISCOVERY 5-Plex procedure
Lung tissue at 40x magnification using the DISCOVERY 5-Plex procedure

"To better investigate the complexities of cancer biology and possible treatment strategies, it is increasingly important to detect multiple biomarkers on a single slide," said Ann Costello, Head of Roche Tissue Diagnostics. "The launch of the innovative DISCOVERY 5-Plex procedure advances automation in multiplexing technology, which is expected to play a critical role in cancer research in the future."

As part of the DISCOVERY 5-Plex procedure launch, four new fluorescent kits used for this procedure will be commercially available3 – DISCOVERY FAM Kit, DISCOVERY Rhodamine 6G Kit, DISCOVERY Red 610 Kit and DISCOVERY DCC Kit.

1 Research Use Only. Not for use in diagnostic procedure.
2 Research platform.
3 Availability outside the US is expected two months following this news release. Please inquire with your local country for availability.

About DISCOVERY products
The DISCOVERY product line is the research use only (RUO) portfolio of instruments and reagents developed by Roche Tissue Diagnostics for research in immunohistochemistry (IHC) and in situ hybridization (ISH). Included in the product line are the DISCOVERY ULTRA research instrument to fully automate single or multiplex IHC and ISH applications and a growing line of unique, ready-to-use reagents for full automation that are designed to meet the needs of the research community.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.

Roche Tissue Diagnostics Media Relations
Victoria Valton
Phone: +1 520.247.2780

Photo -


To view the original version on PR Newswire, visit:

Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche receives FDA clearance for its Procalcitonin (PCT) assay to help clinicians effectively assess sepsis risk and manage sepsis patients
2. Global Companion Diagnostics Market Analysis 2015-2020 - Trends, Technologies & Opportunities Report - Key Vendors: Qiagen, Roche, Cypher Genomics
3. Roche submits filing to FDA for HbA1c testing solution to help meet increasing demand for HbA1c testing of people with diabetes
4. Europe Vitamin D Testing Market Analysis 2015-2019 - Key Vendors are Abbott Diagnostics, Biomeriux, Diasorin, Quest Diagnostics, Roche Diagnostics & Siemens Healthcare Diagnostics
5. Global Self-monitoring Blood Glucose Devices Market 2015-2019 with Abbott Laboratories, Arkray, Bayer Healthcare, LifeScan & Roche Diagnostics
6. World Immunotherapy Drugs Drug, Epidemiology, Regulatory and Pipeline Analysis Market 2015-2020 - Key Players for the $73 Billion Market are Amgen, GSK, Merck, Novartis & Roche
7. Roche Submits Anti-Mullerian Hormone Assay for FDA Approval
8. Global Protein Therapeutics Market 2016-2020 - Key Vendors are AbbVie, Amgen, F.Hoffmann-La Roche, Johnson & Johnson, Merck & Novo Nordisk
9. Drug Delivery Technology Market 2015-2020 - Pfizer, Roche, Johnson & Johnson Services, Novartis & Bayer are Key Players in the $1.5 Billion Industry
10. Roche And Upsher-Smith Announce License Agreement To Develop Novel VAP-1 Inhibitor
11. Orphan Drugs Market 2015-2019 - Key Vendors are Bristol-Mayer Squibb, Celgene, F.Hoffmann La Roche, Novartis & Pfizer
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):